GSK Reports P-I/II Study Updates of GSK3943104 HSV Vaccine
Shots:
- GSK has concluded the primary data analysis from its P-II part of P-I/II (TH HSV REC-003) study assessing the effectiveness of GSK3943104 herpes simplex virus (HSV) vaccine candidate
- The study could not reach the 1EP and hence, GSK3943104 will not advance to further trials. No new safety signals were identified
- The study will continue for safety monitoring and follow-up data collection, providing insights into recurrent genital herpes. GSK is collaborating with investigators to keep participants informed
Ref: GSK | Image: GSK
Related News: GSK Highlights Full Results from the P-III (SWIFT-1 and SWIFT-2) Trials of Depemokimab for Treating Severe Asthma at ERS 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
